EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Application of probiotic therapy in nonalcoholic fatty liver disease: mediating mechanism and future perspective

Xing-Yu Luo, Wei-Bin Huang, Chuang-Hui Lu, Wu Gu, Zi-Xuan Feng, Sui Shen, Ming-Zheng Chen, Shu-Sen Zheng, Zhe Yang

Frontiers in Cellular and Infection Microbiology · 2025

DOI: 10.3389/fcimb.2025.1638372 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Xing-Yu Luo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan (Hang…. Hauptthemen laut MEDLINE: Probiotics, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nonalcoholic fatty liver disease (NAFLD) has a global prevalence of 20%-33%, and has become the main cause of chronic liver disease. Apart from lifestyle modification therapy, there is currently no definitive pharmacological treatment, thus there is an urgent need to find effective intervention strategies to treat NAFLD. With the discovery of the important role of gut microbes in the pathogenesis of NAFLD, research on the prevention and treatment of non-alcoholic fatty liver disease by probiotics is increasing. At present, many studies have confirmed the role of probiotic regulation in the treatment of NAFLD, which can reduce the level of transaminase and liver fibrosis in patients and protect the liver. The clinical application of probiotics includes single species such as Lactobacillus and Bifidobacteria , as well as synbiotics with different compositions. This article reviews the therapeutic effects of probiotics on NAFLD and the mechanisms by which probiotics directly or indirectly affect the disease. Further research is needed to fully understand the specific underlying mechanisms between probiotics, gut microbes, and NAFLD, and more large-scale clinical trials are needed to evaluate probiotics for the treatment of NAFLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsNon-alcoholic Fatty Liver DiseaseHumansGastrointestinal MicrobiomeSynbioticsLactobacillusAnimalsBifidobacteriumLiver

Stichwörter der Autor:innen

applicationfuture perspectivemediating mechanismnonalcoholic fatty liver diseaseprobiotic

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren…
  • School of Medicine, Wenzhou Medical University, Wenzhou, China.
  • Graduate School, Zhejiang Chinese Medical University, Hangzhou, China.
  • School of Clinical Medicine, Hangzhou Normal University, Hangzhou, China.
  • Department of Hepatobiliary and Pancreatic Surgery, Shulan (Boao) Hospital, Boao, China.

Zitieren

APA

Luo, X. Y., Huang, W. B., Lu, C. H., Gu, W., Feng, Z. X., Shen, S., Chen, M. Z., Zheng, S. S., & Yang, Z. (2025). Application of probiotic therapy in nonalcoholic fatty liver disease: mediating mechanism and future perspective. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1638372

Vancouver

Luo XY, Huang WB, Lu CH, Gu W, Feng ZX, Shen S, et al. Application of probiotic therapy in nonalcoholic fatty liver disease: mediating mechanism and future perspective. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1638372

BibTeX
@article{Luo2025,
  author = {Luo, Xing-Yu and Huang, Wei-Bin and Lu, Chuang-Hui and Gu, Wu and Feng, Zi-Xuan and Shen, Sui and Chen, Ming-Zheng and Zheng, Shu-Sen and Yang, Zhe},
  title = {Application of probiotic therapy in nonalcoholic fatty liver disease: mediating mechanism and future perspective},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2025},
  doi = {10.3389/fcimb.2025.1638372}
}
Kostenlos starten →